

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B11

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/28, 5/24, 15/00, 15/09, 15/63, 5/10	A1	(11) International Publication Number: WO 98/21316 (43) International Publication Date: 22 May 1998 (22.05.98)
(21) International Application Number: PCT/US97/20783 (22) International Filing Date: 14 November 1997 (14.11.97) (30) Priority Data: 08/749,527 15 November 1996 (15.11.96) US (71) Applicant: THE NEW YORK BLOOD CENTER, INC. [US/US]; 310 East 67th Street, New York, NY 10021 (US). (72) Inventor: REID, Marion, E.; 504 East 63rd Street, New York, NY 10021 (US). (74) Agents: BARON, Ronald, J. et al.; Hoffmann & Baron, LLP, 350 Jericho Turnpike, Jericho, NY 11753 (US).		(81) Designated States: AU, CA, CN, IL, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: METHOD OF MAKING MONOCLONAL ANTIBODIES USING POLYMORPHIC TRANSGENIC ANIMALS (57) Abstract The invention relates to a method for making monoclonal antibodies having pre-defined specificity of an epitope characteristic of or unique to a single form of a polymorphic protein. The method includes constructing a first transgenic animal to express a first form of a polymorphic protein encoded by a first allele of a gene encoding the protein; constructing a second transgenic animal to express a second form of the polymorphic protein encoded by a second allele of the gene encoding the protein; and immunizing the first transgenic animal with cells from the second transgenic animal expressing the second form of the polymorphic protein to induce an immune response in the first transgenic animal yielding an antibody specific for an epitope peculiar to the second form of the polymorphic protein. The invention further includes hybridoma cells secreting a monoclonal antibody specific for the second form of the protein. The invention is particularly advantageous in the context of making monoclonal antibodies and derivative reagents specifically identifying polymorphic blood group proteins, such as the Duffy gp-Fy protein.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHOD OF MAKING MONOCLONAL ANTIBODIES USING POLYMORPHIC
TRANSGENIC ANIMALS**

BACKGROUND OF THE INVENTION

The invention relates to methods of making antibodies. More specifically, the
5 invention relates to the selective production of monoclonal antibodies having predefined
specificity.

Almost a century ago, the discovery of ABO blood groups by Karl Landsteiner (1901)
led to the development of routine blood grouping procedures in the practice of pretransfusion
testing performed today. This testing depends on agglutination resulting from the interaction
10 between the red blood cells (RBCs) and their cognate antibodies. Historically, human-source
reagents have been used for blood group antigen typing. From time to time attempts have
been made to use non-human reagents for blood grouping. Injection of human RBCs to
animals, such as mice and rabbits, often results in production of a mixture of antibodies which
require extensive absorption or purification for use to detect a single polymorphic determinant.
15 However, with the advent of the ability to produce monoclonal antibodies (MAbs) having
predefined specificities as described in the mid-seventies (Kohler et al. 1975), and in view of
the legally restricted immunization of individuals with allogeneic RBCs, a new era began in the
blood typing industry.

In producing these new monoclonal antibodies, after immunization of mice with
20 appropriate antigens (e.g., RBCs), an antibody-secreting spleen cell is isolated and fused with
an "immortal cell" (a myeloma cell line), to create a hybrid cell called a "hybridoma." The
resulting hybridoma uniquely secretes the antibody of interest into the culture medium, but is
also immortal, thereby capable of acting as a continuous source of the antibody.

The first murine MAb-based blood typing reagent, an anti-M, was licensed by the Food
25 and Drug Administration in 1984 and since that date, MAb reagents for ABO typing have
replaced those prepared from plasma from human donors. MAbs have the advantages of
unlimited supply, batch-to-batch consistency, absence of contaminating antibody specificities,
and minimal biohazard risk to blood typing staff.

While efforts have been concentrated on making MAbs using the mouse hybridoma
30 system, new techniques keep on developing. In vitro infection of human B-lymphocytes with

Epstein-Barr virus (EBV) results in production of transformed, immunoglobulin-secreting lymphoblastoid cells which survive in tissue culture indefinitely and continue to secrete specific antibodies. EBV-transformed human lymphoblastoid cell lines can be fused with a mouse/human myeloma cell line to make MABs. In this fashion, human anti-D, anti-C and anti-E have been made (Doyle et al. 1985; Crawford et al. 1983). However, the major limitation of this technique is the need for lymphocytes from recently immunized human donors. Thus, this is not an effective method for producing a broad range of blood grouping reagents.

Enriched RBC membrane proteins and synthetic peptides have also been used to immunize animals. Unfortunately, limited success has been obtained due to the inability of the animal to recognize blood group polymorphisms, or because the antigens are only expressed if the protein is embedded in the RBC membrane.

While monoclonal technology has advanced substantially and concerted efforts have been made in many institutions, it has not yet proven possible to make MAB reagents with certain specificities, notably anti-Fy^a and anti-Fy^b. In addition, as human source material, e.g., antibodies of sufficient potency, becomes harder and harder to obtain, it is inevitable that MAB reagents will be needed to replace polyclonal reagents. It is obvious that new approaches are needed if MABs with specificities that are not currently available are to be made.

In view of the above considerations, it is clear that existing methods for making antibodies are limited. Moreover, it is evident that existing blood typing reagents based on antibodies are limited in both quality and quantity, necessitating new sources of such reagents.

Accordingly, it is one of the purposes of this invention to overcome the above limitations in the manufacture of antibodies, by providing a method which enables designed production of antibodies, particularly monoclonal antibodies to have particular pre-defined specificities. The availability of such designer antibodies thereby enables the manufacture and production of reagents and methods of detecting expression specific proteins which are presently either difficult or even impossible to identify by conventional methods. Therefore, it is another purpose of the invention to provide a method of making a wide range of MABs capable of use for typing blood samples, investigating functions of proteins, and developing therapeutic reagents.

SUMMARY OF THE INVENTION

It has now been discovered that these and other objectives can be achieved by the present invention, which provides a method for making an antibody, comprising:

constructing a first transgenic animal to express a first form of an exogenous polymorphic protein encoded by a first allele of a gene encoding the protein;
constructing a second transgenic animal to express a second form of the polymorphic protein encoded by a second allele of the gene encoding the protein;

immunizing the first transgenic animal with cells from the second transgenic animal expressing the second form of the polymorphic protein to induce an immune response in the first transgenic animal yielding an antibody specific for an epitope characteristic of the second form of the polymorphic protein.

The method preferably further comprises isolating from the first transgenic animal a lymphoid cell capable of producing the antibody, as well as the cell isolated thereby. More preferably, the method further comprises fusing the isolated antibody-producing lymphoid cell with an immortal cell to provide an antibody-producing hybridoma cell.

The invention, therefore, provides a method of making a hybridoma cell which produces a monoclonal antibody having specificity for an epitope uniquely identifying or characteristic of a single form of a polymorphic protein. The invention further includes the hybridoma cell produced by the method, as well as the monoclonal antibody produced by the hybridoma cell.

The method of the invention can be employed in the context of an exogenous polymorphic protein which is expressed on a cell membrane. Preferably, the polymorphic protein is a blood group protein. More preferably, the blood group protein is gp-Fy protein. It is preferred that the polymorphic protein is a human polymorphic protein.

Preferably, the first transgenic animal and the second transgenic animal are both transformed from animals of one inbred strain. It is further preferred that the first and second transgenic animals are mice.

The invention further includes a hybridoma cell, preferably one that cannot routinely be made by conventional or standard methods known in the art. The hybridoma cell is produced by a method comprising:

constructing a first transgenic animal to express a first form of an exogenous polymorphic protein encoded by a first allele of a gene encoding the protein;

constructing a second transgenic animal to express a second form of the polymorphic protein encoded by a second allele of the gene encoding the protein;

5 immunizing the first transgenic animal with cells from the second transgenic animal expressing the second form of the polymorphic protein to induce an immune response in the first transgenic animal yielding an antibody specific for an epitope characteristic of the second form of the polymorphic protein;

10 isolating from the first transgenic animal a lymphoid cell capable of producing the antibody; and

fusing the antibody-producing lymphoid cell with an immortal cell to provide an antibody-producing hybridoma cell.

The hybridoma cell is preferably capable of producing an antibody specific for an epitope characteristic of a form of a polymorphic protein which is a blood group protein, more preferably being capable of producing an antibody specific for an epitope characteristic a form of gp-Fy protein.

The invention also includes an antibody specific for an epitope characteristic of one form of a polymorphic protein, produced by a method comprising:

20 constructing a first transgenic animal to express a first form of an exogenous polymorphic protein encoded by a first allele of a gene encoding the protein;

constructing a second transgenic animal to express a second form of the polymorphic protein encoded by a second allele of the gene encoding the protein;

25 immunizing the first transgenic animal with cells from the second transgenic animal expressing the second form of the polymorphic protein to induce an immune response in the first transgenic animal yielding an antibody specific for an epitope characteristic of the second form of the polymorphic protein; and

isolating the antibody.

The method preferably further comprises:

30 isolating from the first transgenic animal a lymphoid cell capable of producing the antibody; and

fusing the antibody-producing lymphoid cell with an immortal cell to provide a hybridoma cell which produces the antibody.

The antibody is preferably specific for a polymorphic protein which is a blood group protein, more preferably wherein the blood group protein is gp-Fy protein and the monoclonal antibody is specific for an epitope characteristic of one form of gp-Fy protein.

The invention also includes a method for making an antibody, comprising:

constructing a transgenic animal, preferably a transgenic mouse, to express a first form of an exogenous polymorphic protein encoded by a first allele of a gene encoding the protein;

immunizing the transgenic animal with a peptide comprising an epitope characteristic of a second form of the polymorphic protein to induce an immune response in the transgenic animal yielding an antibody specific for the epitope; and

isolating the antibody.

Preferably the method further comprises isolating from the transgenic animal a lymphoid cell capable of producing the antibody. Still more preferably the method further comprises fusing the isolated antibody-producing lymphoid cell with an immortal cell to provide an antibody-producing hybridoma cell.

Preferably, the polymorphic protein is expressed on a cell membrane, e.g., a blood group protein, such as gp-Fy protein. Preferably, the polymorphic protein is a human polymorphic protein.

These and other advantages of the present invention will be appreciated from the detailed description and examples which are set forth herein. The detailed description and examples enhance the understanding of the invention, but are not intended to limit the scope of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Preferred embodiments of the invention have been chosen for purposes of illustration and description, but are not intended in any way to restrict the scope of the invention. The preferred embodiments of certain aspects of the invention are shown in the accompanying drawing, wherein:

Figure 1 is a diagram of the proposed topography of the Duffy glycoprotein within the red cell membrane.

Figure 2 is a schematic illustration of a method of constructing transgenic mice expressing *FY*B*.

5 Figures 3A and 3B together constitute a schematic illustration of the Duffy genomic DNA sequence (*FY*B*) used to produce transgenic mice.

Figure 4 is a digitized image of PCR amplification products derived from Duffy genomic DNA sequence showing integration into the genome of transgenic mice.

10 Figure 5 is a schematic illustration of a method of producing monoclonal antibodies by the transgenic animal/hybridoma technique of the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed to a method of making antibodies having pre-defined specificity for one form of a polymorphic protein. The invention permits the manufacture of monoclonal antibodies (MAbs) with pre-defined specificities, including MAbs that have eluded
15 production using established protocols despite aggressive efforts in many laboratories. In particular, several specificities to blood group antigens are needed to replace the decreasing supplies of human polyclonal antibodies including, for example: anti-Fy^a, anti-Fy^b, anti-S, anti-e, anti-Kp^a and anti-Js^a.

20 The experience of cloning the gene encoding the Duffy (gp-Fy) protein, of determining the molecular basis of the Fy^a/Fy^b polymorphism, of producing transgenic mice whose red blood cells (RBCs) express the human Fy^b antigen, have been found to make the Duffy polymorphism an ideal system in which to produce MAbs. Our development of MAbs anti-Fy^a and anti-Fy^b constitute a model system which demonstrates the general utility of using
25 transgenic mice to develop MAbs for any polymorphism which is carried on a protein whose gene has been cloned and the molecular basis of which has been determined. Thus, a comprehensive range of MAbs can now be made as blood typing reagents, as tools for the investigation of biological function, and as possible therapeutic applications.

30 The polymorphic protein used in the method can be any protein having two or more immunologically differentiable forms. Generally, each form of the protein is encoded by an allele of the same gene. Thus, for any gene where two (or more) alleles are known and are

recognized as defining polymorphism in the expressed gene products, the method of the invention can be used to generate monoclonal antibodies against epitopes defined by the polymorphism, if such exist. The protein, therefore, is a protein which is at least potentially recognizable as non-self by an animal which does not express the particular protein.

5 The protein is preferably a protein which is expressed on or in a cell membrane, such as a cell surface antigen, e.g., a receptor, an enzyme, etc. One highly preferred protein is the Duffy antigen, also known as the gp-Fy protein, having a polymorphism characterized by gp-Fy^a and gp-Fy^b expressed proteins. The Duffy polymorphism is described in U.S. application Serial No. 08/140,797, filed on October 21, 1993, and in U.S. application Serial
10 No. 08/749,543, filed on November 15, 1996, the entire disclosures of which are incorporated by reference herein.

Other blood group antigens can be used to develop monoclonal antibodies according to the method of the invention. For example, the Rh group and the Kell group are known to include allelic polymorphisms which can be exploited according to the invention. Other blood
15 group proteins or red blood cell membrane proteins having known polymorphism are shown in Table 1.

TABLE 1

Some Red Cell Blood Group Antigens with One Amino Acid Substitution

Blood Group System	Antigen Polymorphism	Codon	Residue No.	Amino Acid
MNS	s⇒S	ATG⇒ACG	29	Met⇒Thr
	ENEH⇒Hut	ACG⇒AAG	28	Thr⇒Lys
	ENEH⇒VW	ACG⇒ATG	28	Thr⇒Met
Rh	C⇒c	TCT⇒CCT	103	Ser⇒Pro
	E⇒e	CCT⇒GCT	226	Pro⇒Ala
	Tar (-)⇒(+)	CTX⇒CCX	110	Leu⇒Pro
Kell	k⇒K	ACG⇒ATG	193	Thr⇒Met
	Kp ^b ⇒Kp ^a	CGG⇒TGG	281	Arg⇒Trp
	Kp ^b ⇒Kp ^c	CGG⇒CAG	281	Arg⇒Gln

	Js ^b ⇒Js ^a	CTC⇒CCC	597	Leu⇒Pro
	K11⇒K17	GTC⇒GCC	302	Val⇒Ala
	U1 ^a (-)⇒(+)	GAT⇒GTA	494	Glu⇒Val
	K17(-)⇒(+)	GTC⇒GCC	302	Val⇒Ala
	K1 (-)⇒(+)	ACG⇒ATG	193	Thr⇒Met
Duffy	Fy ^b ⇒Fy ^a	GAT⇒GGT	44	Asp⇒Gly
Diego	Di ^a ⇒Di ^b	CCX⇒CTX	854	Pro⇒Leu
	Wr ^b ⇒Wr ^a	GAG⇒AAG	658	Glu⇒Lys
	Wd(-)⇒(+)	GTG⇒ATG	557	Val⇒Met
	Rb ^a (-)⇒(+)	CCA⇒CTA	548	Pro⇒Leu
	WARR(-)⇒(+)	ACX⇒ATX	552	Thr⇒Ile
	ELO(-)⇒(+)	CGG⇒TGG	432	Arg⇒Trp
	Fr ^a (-)⇒(+)	GAG⇒AAG	480	Glu⇒Lys
	Wu(-)⇒(+)	GGC⇒GCC	565	Gly⇒Ala
	Bp ^a (-)⇒(+)	ACA⇒AAA	569	Asn⇒Lys
	Hg ^a (-)⇒(+)	CGT⇒TGT	656	Arg⇒Cys
	Mo ^a (-)⇒(+)	CGT⇒CAT	656	Arg⇒His
Yt	Yt ^a ⇒Yt ^b	CAC⇒AAC	322	His⇒Asn
Colton	Co ^a ⇒Co ^b	GCG⇒GTG	45	Ala⇒Val
Landsteiner-Wiener	LW ^a ⇒LW ^b	CAG⇒CGG	70	Gln⇒Arg
Cromer	Cr ^a (+)⇒(-)	GCA⇒CCA	193	Ala⇒Pro
	Tc ^a ⇒Tc ^b	CGT⇒CTT	18	Arg⇒Leu
	WES ^b ⇒WES ^a	CTX⇒CGX	48	Leu⇒Arg
Indian	In ^b ⇒In ^a	CGG⇒CCG	26	Arg⇒Pro

The invention, therefore permits the generation of panels of blood typing antibodies (e.g., hemagglutination reagents) against any or all of the various expressed epitopes of any or all of these blood group proteins. But the invention is useful in general to develop monoclonal

antibodies against any polymorphic cell surface membrane protein, especially those proteins against which monoclonal antibody cannot be routinely made by conventional methods.

The invention can further be used to identify polymorphisms in proteins where none has been previously identified. For example, if two or more alleles of a gene are known, each encoding a different form of the protein in question, then the transgenic method can be used to determine whether such polymorphism corresponds to epitopic differences sufficient to induce an immune reaction. Similarly, other mechanisms associated with protein polymorphism, e.g., differential splicing at the mRNA level, can be studied and exploited by means of the invention. The induction of a cell secreting antibody specifically reactive with the protein used as the putative immunogen provides substantive evidence of epitopic difference. A utility of such an approach is found in the ability to generate information about a protein where conventional immunological characterization reagents and methods fail to yield adequate information. For example, conventional hydropathy analysis may produce ambiguity of interpretation as to whether a difference in primary structure lies within or without the cell membrane. The production of a monoclonal antibody having specificity for one form of the protein but not another would constitute evidence of a difference in extracellular conformation.

The cloning and sequencing of the human Duffy gene has enabled numerous utilities related to characterizing the normal physiological role of the gp-Fy protein as well as the abnormal role of the protein as a malarial binding ligand. Of particular interest for the present invention, the knowledge of the molecular basis of the Duffy blood group polymorphism enables the construction of transgenic animals to express heterologous Duffy protein. Various transgenic techniques are known, and certain of these techniques can yield heritability of the transgene. See, e.g., Pinkert et al. (1995) for an overview of these techniques, and the documents cited there for greater detail. For example, the invention takes advantage of transgenic mammals transformed by integration of an expressible transgene comprising a heterologous Duffy-related nucleic acid sequence into the genome of the mammal. Such transgenic animals express a Duffy protein normally expressed in erythrocytes of another species, preferably a human Duffy protein.

The animal used to create the transgenic model can be any species, but is preferably a mammal, for example, mice, rats, goats, sheep, pigs, cats, dogs, rabbits, horses or another

mammal. Mice are particularly preferred. Moreover, it is preferred that the animal to be transformed be inbred to have a high degree of genetic uniformity between individuals, so that no interfering immune response is generated upon introduction of the cells from one animal into another. Numerous strains of inbred animals, most notably mice, are commercially available. The skilled artisan will appreciate advantages derived from the animal having a relatively well characterized genome, and especially a well characterized immune system. It is further preferred that the autologous gene or genes, if any, which is(are) evolutionarily related to the heterologous gene be at least partially understood at the molecular level.

By employing transgenic animals expressing only one form of a polymorphic protein, the method of the invention ensures that the only immunological difference between cells of the transgenic mouse and the cells or protein used as the immunogen will be the polymorphism. This approach virtually guarantees that any immune response raised by the transgenic mouse will raise an immune response directed solely against the single polymorphic difference. This approach has the potential of allowing production of MAbs that are currently unavailable, as well as MAbs specific for antigens that require the milieu of the cell membrane to be expressed.

To date, no MAb anti-Fy^a or anti-Fy^b have been produced. Clinically significant antibodies of both specificities have been described (Giblett 1977; Badakere et al. 1970; Freisleben 1951; Beattie 1988) and it is important to be able to type donor and patient blood for the corresponding antigens in the pre-transfusion setting. Attempts to make specific MAb anti-Fy^a and anti-Fy^b have included injection of mice or rabbits with human RBCs, enriched Duffy protein or synthetic peptides, but these methods have been unsuccessful. Use of the purified Duffy protein or peptides as immunogens has resulted in production of antibodies to the Duffy protein but not to the polymorphism. These findings suggest that the Fy^a and Fy^b antigens are expressed only if the Duffy protein is within the milieu of the RBC membrane.

Thus, to resolve this ambiguity, the present method can be used to make Fy^a transgenic mice, with RBCs from these mice being injected into existing Fy^b transgenic mice. RBCs from the Fy^b transgenic mice are injected into the Fy^a transgenic mice. This cross-immunization protocol, i.e., immunization between allelic transgenic mice, provides an exquisite means by which to make MAbs with specificities not currently available. Indeed, following this approach, a more comprehensive range of MAb specificities can be made.

The Fy^a antigen was first discovered on erythrocytes in 1950 using an antibody (called anti-Fy^a) in the serum of a multitransfused hemophiliac patient (Cutbush 1950). Just a year later, its antithetical antibody, anti-Fy^b was reported (Ikin et al. 1951). The Duffy blood group system has expanded modestly over years, however, intense interest in Duffy was triggered when the gene encoding Duffy glycoprotein (gp-Fy) was cloned in 1993 (Chaudhuri et al. 1993), and the role of gp-Fy in the RBC membrane was elucidated (Neote et al. 1994; Horuk et al. 1993; Iwamoto et al. 1996).

Gp-Fy, which is predicted to have seven transmembrane α -helices, is encoded by a gene on the long arm of chromosome 1 (Donahue et al. 1968). The protein has an apparent molecular mass of M_r 35,000 to 43,000 on a polyacrylamide gel. The antigens Fy^a and Fy^b, located on the N-terminal extracellular domain of gp-Fy (Fig. 1) (Chaudhuri et al. 1995; Iwamoto et al. 1995; Mallinson et al. 1995), define four phenotypes in this blood group system: Fy(a+b-), Fy(a-b+), Fy(a+b+) and Fy(a-b-). In whites, the first three phenotypes are commonly observed, and Fy(a-b-) individuals are extremely rare. However, the Fy(a-b-) phenotype among blacks is frequent in African-Americans and reaching almost 100% in people from some areas of West Africa (Race et al. 1975). In Fy(a-b-) individuals of African descent, the absence of Duffy antigens is associated with an absence of Duffy glycoprotein in the RBC membrane due to a single nucleotide substitution of GATA to GACA in the erythroid promoter (Tournamille et al. 1995). Thus, Duffy mRNA was detected in many other tissues in both Duffy positive and Duffy negative individuals (Neote et al. 1994; Iwamoto et al. 1996; Chaudhuri et al. 1995).

Anti-Fy^a and anti-Fy^b are usually IgG molecules and are of variable clinical significance. Mild hemolytic transfusion reactions have been attributed to examples of these antibodies. Two other antibodies, anti-Fy3 and murine MAb anti-Fy6 bind to the Duffy glycoprotein (Albrey et al. 1971; Nichols et al. 1987). Fy3 and Fy6 are present on all RBCs except those of the Fy(a-b-) phenotype. Using a MAb anti-Fy3, the Fy3 antigen has been shown to reside on the last extracellular loop of the gp-Fy protein (Fig. 1) (Lu et al. 1995). A MAb anti-Fy6, produced by immunizing mice with pooled red cells (Riwom et al. 1994), binds to the N-terminal extracellular region between amino acids 31 and 40 of the gp-Fy protein (Hausman et al. 1996). The distribution of Fy6 on RBCs of non-human

primates differs from Fy^a, Fy^b and Fy³ (Nichols et al. 1987). MAb anti-Fy⁶ has been invaluable in the isolation of gp-Fy (Riwom et al. 1994; Chaudhuri et al. 1989).

Apart from the fact that Fy^a and Fy^b are immunogenic in humans and are frequently involved in blood transfusion, the biochemical and functional characterization of the gp-Fy is of major importance. In addition to cloning the gene encoding gp-Fy by Chaudhuri and coworkers (described in U.S. Application Serial No. 08/140,797, filed on October 21, 1993), the functions of gp-Fy as a chemokine receptor and its involvement in the process of invasion of human RBCs by malarial parasites *Plasmodium vivax* and *P. knowlesi* (a simian parasite) were elucidated (Chaudhuri et al. 1989; Miller et al. 1975; Miller et al. 1976; Barnwell et al. 1989). Horuk and coworkers (1993) showed that gp-Fy acts as a receptor for chemokines responsible for such processes as cell interaction, cell growth and inflammation, namely interleukin-8 (IL-8), melanoma growth stimulatory activity (MGSA), RANTES and monocyte chemotactic protein 1 (MCP-1). However, there is no subsequent signal transduction demonstrated upon binding. It has been suggested that gp-Fy absorbs excess cell-signaling molecules (Darbonne et al. 1991). Despite the intensive work performed on the gp-Fy, the role of Duffy antigens in invasion by malaria parasites and in the binding to chemokines is not clear. What is clear is that structural information on the gp-Fy is needed to understand the process of the interaction between the merozoite or chemical ligands and its RBC membrane receptor. Once anti-Fy^a and anti-Fy^b MAbs are available, they can be used to further investigate the specific topology of the gp-Fy protein that contributes to the Fy^a/Fy^b epitopes.

The genes encoding Fy^a and Fy^b antigens have been cloned. Transgenic mice have been constructed, whose RBCs express the human Fy(a-b+) phenotype, by injecting genomic DNA into mouse zygotes. This knowledge can be used to generate transgenic mice expressing the human Fy(a+b-) phenotype. The offspring of these transgenic mice are expected to carry either human Fy^a or Fy^b antigens on their RBCs. Blood cells isolated from one group of transgenic mice are used to immunize the other group. This approach overcomes the observed problem that certain antigens can only induce an immune response by their close relatives, but not by lower species. Furthermore, it significantly limits the contamination of antibodies obtained by injection of human RBCs into mice. Perhaps most significantly, the only difference between the RBCs of the transgenic mouse being immunized and the transgenic mice RBCs being used as the immunogen is the Duffy antigen. Thus, it is

highly probable that the mouse will mount an immune response to the Fy^a or Fy^b polymorphism. After immunization, the spleen of the immunized mice is isolated, fused to myeloma cells and processed by conventional hybridoma technique to select hybrids secreting anti-Fy^a and anti-Fy^b. Such MAbs will be useful in the replacement of human anti-serum reagents in the practice of blood typing and in the investigation of the topology and function of the Duffy glycoprotein.

In addition, study on the capability of stimulation of immune response with the truncated protein or the intact cells will provide important topological information of gp-Fy. Nonetheless, the transgenic mice constructed will be extremely useful to elucidate the functions and biological role of the Duffy protein, and that would serve as an excellent animal model to develop any possible therapeutic treatments for chemokine disorders or the infection of malarial parasite in the third world.

The following examples are provided to assist in a further understanding of the invention. The particular materials and conditions employed are intended to be further illustrative of the invention and are not limiting upon the reasonable scope thereof.

EXAMPLE 1: Preparation of Transgenic Mice Expressing gp-Fy^b Protein

Transgenic mice have been constructed to express the human Duffy gp-Fy^b antigen using a method substantially in accordance with that illustrated in Figure 2. A 3523 bp genomic DNA fragment containing *FY*B* coding sequence and ~1.5 kb upstream and ~1 kb downstream flanking sequences (SEQ ID NO:1; see also Figure 3A and 3B) was amplified by the polymerase chain reaction using *FY*-specific primers (sense: 5-CTGCAGGGGTAGATGCCCTTTCTC-3 (SEQ ID NO:2); antisense: 5-GAATTCCAAGCAGAAGATGAATC-3 (SEQ ID NO:3)). The amplified fragment was cloned in the pBluescript vector (Stratagene). Plasmid DNA was purified by two-round centrifugation in CsCl gradients. The fragment containing the inserted genomic *FY*B* gene was excised by appropriate restriction enzymes and separated on a gel followed by DNA purification. The pure DNA fragment was reconstituted to a concentration of approximately 5 µg/mL and was used to construct transgenic mice.

The purified DNA fragment was micro-injected into the male pronucleus of fertilized eggs of the B6/CBA F1 mouse (Jackson Laboratory, Bar Harbor, ME), which had been

removed from the oviducts of a female mouse that had mated the night before. The zygotes with the insertion were transferred to the oviducts of 0.5-day pseudo-pregnant females and allowed to develop into embryos. Ten females became pregnant, producing 60 pups.

Four weeks after birth, DNA was prepared from tail clips of each baby animal using
5 proteinase K digestion and ethanol precipitation. The DNA was tested for *FY* sequence integration by dot blot hybridization with a probe derived from the Duffy genomic DNA or by PCR amplification using *FY*-specific primers. In the PCR, 200 ng of the genomic DNA was amplified with the Duffy-specific primers with Taq polymerase. The PCR reaction was carried out for 30 cycles as follows: 30 s at 94°C, 30 s at 65°C, and 3 min at 72°C. Ten microliters
10 (10 µL) of the reaction mixture was run on a 1% agarose gel, using a 1 kb DNA marker, with a non-transgenic mouse sample as a control. Figure 4 shows representative PCR results, with a DNA marker (lane 1), DNA from a non-transgenic mouse control (lane 2), and DNA samples from 12 transgenic mice (lanes 3-14). The dot blot hybridization and PCR
amplification showed that 11 out of the 60 mice (18% transduction rate) had successful
15 integration of the human Duffy genomic DNA into their chromosome, and more than one copy of *FY* was observed (data not shown).

Expression of the exogenous gene was examined by hemagglutination. Serological studies were performed by collecting blood from each animal showing successful integration of human Duffy DNA by puncture of the orbital plexus under an anesthetized condition. The
20 isolated RBCs were tested for the presence of human Fy^b antigen by hemagglutination using murine MAbs anti-Fy3, anti-Fy6, and human anti-Fy^b. Of the 11 transgenic mice having the Duffy gene incorporated, RBCs from four mice showed the expression of the expected cognate antigens. These results are shown in Table 2, below, which summarizes immunological data concerning red cells from the 11 mice as compared to human red cells.

TABLE 2

	Erythrocytes	anti-Fy3	Anti-Fy6	Anti-Fy ^b	PCR
5	Human	++	++	++	Positive
	Mouse #1	++++	++	++	Positive
	Mouse #2	++++	++	++	Positive
	Mouse #3	-	-	-	Positive
	Mouse #4	-	-	-	Positive
10	Mouse #5	++	++	++	Positive
	Mouse #6	-	-	-	Positive
	Mouse #7	+++	+	++	Positive
	Mouse #8	-	-	-	Positive
	Mouse #9	-	-	-	Positive
15	Mouse #10	-	-	-	Positive
	Mouse #11	-	-	-	Positive

These data indicate that not all of the integration of *FY*B* gene occurred at the chromosomal site which is being actively transcribed. However, approximately 7% of the transfected animals actively transcribed *FY* and synthesized (expressed) the Duffy Fy^b protein. Furthermore, it is demonstrated that the integrated DNA sequence contains all of the information necessary for Duffy promoter activity and its expression in erythroid specific manner. The red cells of the transgenic mice are serologically identical to a Duffy-positive human having Fy(a-b+) erythrocytes. These agglutination data imply that the expressed human Duffy protein was folded onto the mouse RBC membrane preserving its native (i.e., human) conformational structure and antigenic sites.

It is worth noting that random integration of the Duffy genomic DNA into mouse chromosome demonstrably works well in expression of the Duffy protein. Even so, targeted integration into an appropriate chromosome may be necessary for producing desired transgenic animals in other cases. Such targeted transformation can be accomplished by conventional methods, and given the information provided herein is within the skill of the artisan

EXAMPLE 2: Construction of Transgenic Mouse Expressing Human Fy^a Antigen

The method described in Example 1 is directly adaptable for the construction of a transgenic animal expressing the Fy^a antigen. In this case, the genomic DNA of *FY*A* are either amplified from an individual of Fy(a+b-) phenotype, as described above, or obtained by performing site-directed mutagenesis at nucleotide 131 of the open reading frame (ORF) (A¹³¹-G). The Fy^a and Fy^b antigens differ as a result of single nucleotide difference (G¹³¹ or A) encoding amino acids Gly⁴⁴ (Fy^a) or Asp (Fy^b) in the N-terminal extracellular domain of the Duffy glycoprotein. A vector is constructed containing the *FY*A* DNA, and mice are transfected. The resulting transformed mice express human Fy^a on their red cell surfaces, having a conformation suitable for producing an agglutination reaction identical to that of native human Fy^a. Once transformed, the transgenic mice can be bred to obtain the homozygous transgenic mice, and further bred to produce a stock of animals having the same DNA insertion.

EXAMPLE 3: Preparation of Soluble Peptides That Express Fy^a or Fy^b Antigens

To examine if the extracellular N-terminal 65 amino acids are sufficient to stimulate an immune response to Fy^a or Fy^b antigens, Duffy-based peptides can be synthesized using recombinant DNA technology. The fragment encoding the N-terminal hydrophilic domain of the gp-Fy is amplified by using appropriate primers (see Figures 3A and 3B) with a purification tag of six histidine and a proteolytic site in front of it. To ensure that the truncated gp-Fy is immunogenic, the recombinant peptide might require conjugation to an inert carrier (MAP core) or dimerized through a recombination PCR procedure. The resulting PCR fragment is sequenced to ensure the perfect amplification and then inserted into an eukaryotic expression vector. As Fy^b has been successfully expressed in K562 cells, a human erythroleukemic cell line (Chaudhuri et al. 1994), the eukaryotic vector can be transiently transfected into K562 cells by calcium phosphate technique. The supernatant containing the truncated version of gp-Fy is harvested between 48 to 72 hours after transfection and eluted through either an ion exchange column or an affinity column with the conjugation of murine MAb anti-Fy6. The purified protein can be injected into the transgenic mice as the appropriate immunogen.

EXAMPLE 4: Immunization of Fy^a and Fy^b Transgenic Mice Using Recombinant**Peptides**

Recombinant Fy^a peptide is injected into the Fy^b transgenic mice prepared in Example 1 using a standard immunization protocol (Rudbach et al. 1995). Likewise, recombinant Fy^b peptide is injected into the Fy^a transgenic mice prepared according to Example 2. Serum is collected and examined for the production of anti-Fy^a and anti-Fy^b, respectively. Since the human gp-Fy has become one of the native proteins on the RBCs of these transgenic mice during embryonic development, immunization with human-origin antigen will likely produce a stronger immune response in them as compared to that in the original nontransgenic mice. The immunogenicity of the recombinant peptide is optimized through the use of appropriate adjuvants to yield highly quantitative and qualitative antibodies.

If specific antibody is produced in response to the injected peptide, the monoclonal hybridoma technique is employed as described below. Otherwise, if the soluble peptide does not induce an immune response, this may indicate that the epitopes of Fy^a and Fy^b are associated with other regions (e.g., the extracellular loops) of the Duffy protein or with other membrane proteins. This would suggest that the entire Duffy molecule with a mature conformation on the RBC membrane is needed to create the proper epitope for immunization. Thus, the RBCs of the transgenic mice would be the best immunogen. Moreover, in order to evaluate whether the transgenic mouse that expresses the native human Duffy protein is indeed a better host for immunization, the same procedure can be performed using an original untreated strain.

EXAMPLE 5: Immunization Using Transgenic Mice RBCs Expressing Fy^a or Fy^b

Once the transgenic strains of Fy^a and Fy^b mice are established, a cross-immunization procedure is performed generally in conformity with the method illustrated in Figure 5. The RBCs isolated from each mouse strain are injected subcutaneously and intravenously into the mice of their counter group. We have shown that Fy^b antigens are expressed on the transgenic mouse RBCs as indicated by specific human antiserum (Table 2). As these two sources of RBCs only differ in the expression of either Fy^a antigen or Fy^b antigen, and not any other antigenic sites of the Duffy protein (e.g., Fy3 and Fy6) or other RBC-borne antigens, the polymorphic sites of Fy^a or Fy^b are the only target to produce antibody. This results in a

greater chance of making anti-Fy^a and anti-Fy^b since the presumably higher immunogenic epitopes to mouse immune system are unrecognizable in this protocol. This assumption is based on the finding that immunization of mice with RBCs, purified gp-Fy, or synthetic peptides has only resulted in production of antibodies to the gp-Fy and not to the Fy^a/Fy^b polymorphism.

EXAMPLE 6: Immunization of Non-Transgenic Mice with RBCs from a Transgenic Fy^b Mouse

Since transgenic mice whose RBCs express human Fy^b antigens are available, the cells of these mice can be used to immunize mice of the same wild type strain. If the non-transgenic mice mount an immune response, the preparation of MAbs can be usefully attempted.

EXAMPLE 7: Fusion and Cloning of the Hybridoma Cells Secreting Anti-Fy^a/Fy^b

After final immunization, the mice selected according to satisfactory antibody titers are killed and their spleens are removed. The splenocytes are fused into the mouse myeloma X63-Ag8.653 cells using a standard polyethylene glycol (PEG)/dimethylsulfoxide (DMSO) procedure, followed by HAT selection (Rudbach et al. 1995; Gorny et al. 1994). The mouse myeloma used for fusion is usually a HAT-sensitive variant of the Balb/c-derived myeloma. Although the spleen cell donor is an inbred strain other than Balb/c, the MAb is generated only from cell culture fluids, thereby avoiding the histocompatibility problem. Alternatively, the F1 progeny of a Balb/c:"spleen cell donor" cross, which contains both sets of histocompatibility antigens, can be used to grow the hybridomas.

The supernatant of the hybridoma cells is screened for antibody secretion with antigen-positive and antigen-negative human RBCs by direct hemagglutination or ELISA. Hybridoma cells producing specific antibody are cloned by limiting dilution. The stable cell lines are frozen for future use or expanded in culture for bulk production of antibodies. By this protocol, both IgG and IgM antibodies are obtained.

This result makes possible the use of direct agglutinating monoclonal anti-Fy^a and anti-Fy^b for screening programs to find antigen-negative donors, since currently available reagents require the antiglobulin test and cannot be used to type RBCs with a direct antiglobulin test.

EXAMPLE 8: Evaluation of the Monoclonal Anti-Fy^a and Anti-Fy^b

The monoclonal anti-Fy^a and anti-Fy^b are evaluated for their specificity and sensitivity in comparison to the current reagents by using a large number of blood samples from random donors and by testing rare RBCs with known phenotypes, which are commercially available.

5 Standard hemagglutination techniques are used.

EXAMPLE 9: Characterization of the Monoclonal Anti-Fy^a and Anti-Fy^b Antibodies

The nucleotide sequences of variable domains of anti-Fy^a and anti-Fy^b are identified by sequence analysis with specific primers for this region. As the Fy^a/Fy^b antigen is suggested to be involved in the chemokine binding and in the parasite invasion, the obtained information

10 will be extremely useful for design of an immunotherapeutic agent or a "vaccine" for blocking the interactions between the Duffy protein and its ligands or the parasites.

Thus, while there have been described what are presently believed to be the preferred embodiments of the present invention, those skilled in the art will realize that other and further embodiments can be made without departing from the spirit of the invention, and it is intended

15 to include all such further modifications and changes as come within the true scope of the claims set forth herein.

BIBLIOGRAPHY

The following publications, mentioned in the foregoing specification, are incorporated herein by reference for all that they disclose:

- Giblett ER. "Blood group alloantibodies: An assessment of some laboratory practices,"
5 *Transfusion* 4:299-308 (1977).
- Badakere SS, Bhatia HM. "A fatal transfusion reaction due to anti-Duffy (Fy) case report,"
 Indian J Med Sci 24:562-564 (1970).
- Freiesleben E. "Fatal hemolytic transfusion reaction due to anti-Fy^a ('Duffy')," *Acta Path*
 Microbiol Scand 29:283-286 (1951).
- 10 Beattie KM. "The Duffy blood group system: Distribution, serology and genetics," In: Pierce
 SR, Macpherson CR, eds., *Blood Group Systems. Duffy, Kidd and Lutheran*.
 American Association of Blood Banks, Arlington, VA, pp. 1-25 (1988).
- Landsteiner K. "Über Agglutinationserscheinungen normalen menschlichen Blutes," *Klin*
 Wchr 14:1132 (1901).
- 15 Kohler G, Milstein C. "Continuous cultures of fused cells secreting antibody of predefined
 specificity," *Nature* 256:495-497 (1975).
- Doyle A, Jones TJ, Bidwell JL, Bradley BA. "In vitro development of human monoclonal
 antibody-secreting plasmacytomas," *Human Immunology* 13:199-209 (1985).
- Crawford DH, Barlow MJ, Harrison JF, Winger L, Huehns ER. "Production of human
20 monoclonal antibody to rhesus D antigen," *Lancet* 1:386-388 (1983).
- Cutbush M, Mollison PI, Parkin DM. "A new human blood group," *Nature* 165:188 (1950).
- Ikin EW, Mourant AK, Pettenkofer HJ, Blumenthal G. "Discovery of the expected
 haemagglutinin anti-Fy^b," *Nature* 168:1077-1078 (1951).
- Chaudhuri A, Polyakova J, Zbrzezna V, Williams K, Gulati S, Pogo AO. "Cloning of
25 glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group
 system and the receptor for the *Plasmodium vivax* malaria parasite," *Proc Natl Acad*
 Sci USA 90:10793-10797 (1993).
- Neote K, Mak JY, Kolakowski LF, Jr., Schall TJ. "Functional and biochemical analysis of
 the cloned Duffy antigen: Identity with the red blood cell chemokine receptor," *Blood*
30 84:44-52 (1994).

- Horuk R, Chitnis CE, Darbonne WC, et al. "A receptor for the malarial parasite *Plasmodium vivax*: the erythrocyte chemokine receptor," *Science* 261:1182-1184 (1993).
- Iwamoto S, Li J, Omi T, Ikemoto S, Kajii E. "Identification of a novel exon and spliced form of Duffy mRNA that is the predominant transcript in both erythroid and postcapillary venule endothelium," *Blood* 87:378-385 (1996).
- 5 Donahue RP, Bias W, Renwick JH, McKusick VA. "Probable assignment of the Duffy blood group locus to chromosome I in man," *Proc Natl Acad Sci USA* 61:949-955 (1968).
- Chaudhuri A, Polyakova J, Zbrzezna V, Pogo O. "The coding sequence of Duffy blood group gene in humans and simians: Restriction fragment length polymorphism, antibody and malarial parasite specificities, and expression in nonerythroid tissues in
- 10 Duffy-negative individuals," *Blood* 85:615-621 (1995).
- Iwamoto S, Omi T, Kajii E, Ikemoto S. "Genomic organization of the glycophorin D gene: Duffy blood group Fy^a/Fy^b alloantigen system is associated with a polymorphism at the 44-amino acid residue," *Blood* 85:622-626 (1995).
- 15 Mallinson G, Soo KS, Schall TJ, Pisacka M, Anstee DJ. "Mutations in the erythrocyte chemokine receptor (Duffy) gene: The molecular basis of the Fy^a/Fy^b antigens and identification of a deletion in the Duffy gene of an apparently healthy individual with the Fy(a-b-) phenotype," *Br J Haematol* 90:823-829 (1995).
- Race RR, Sanger R. *Blood Groups in Man*, 6th Ed., Blackwell, Oxford, England (1975).
- 20 Tournamille C, Colin Y, Cartron J-P, Le Van Kim C. "Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals," *Nature Genet* 10:224-228 (1995).
- Albrey JA, Vincent EE, Hutchinson J, et al. "A new antibody, anti-Fy³, in the Duffy blood group system," *Vox Sang* 20:29-35 (1975).
- 25 Nichols ME, Rubinstein P, Barnwell J, Rodriguez de Cordoba S, Rosenfield RE. "A new human Duffy blood group specificity defined by a murine monoclonal antibody: Immunogenetics and association with susceptibility to *Plasmodium vivax*," *J Exp Med* 166:776-785 (1987).

- Lu ZH, Wang ZX, Hadley TJ, Hesselgesser J, Horuk R, Peiper SC. "Localization of the Fy3 epitope of the Duffy antigen/receptor for chemokines (DARC) to the third extracellular loop which is not involved in chemokine binding (abstract)" *Blood* 86(Suppl 1):444a (1995).
- 5 Riwom S, Janvier D, Navenot JM, Benbunan M, Muller JY, Blanchard D. "Production of a new murine monoclonal antibody with Fy6 specificity and characterization of the immunopurified N-glycosylated Duffy-active molecule," *Vox Sang* 66:61-67 (1994).
- Hausman E, Dzik W, Blanchard D. "The red cell chemokine receptor is distinct from the Fy6 epitope," *Transfusion* 36:421-425 (1996).
- 10 Chaudhuri A, Zbrzezna V, Johnson C, et al. "Purification and characterization of an erythrocyte membrane protein complex carrying Duffy blood group antigenicity. Possible receptor for *Plasmodium vivax* and *Plasmodium knowlesi* malaria parasite," *J Biol Chem* 264:13770-13774 (1989).
- Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK. "Erythrocyte receptors for (15 *Plasmodium knowlesi*) malaria: Duffy blood group determinants," *Science* 189:561-563 (1975).
- Miller LH, Mason SJ, Clyde DF, McGinniss MH. "The resistance factor to *Plasmodium vivax* in blacks. The Duffy blood group genotype, FyFy," *N Engl J Med* 295:302 (1976).
- 20 Barnwell JW, Nichols ME, Rubinstein P. "In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by *Plasmodium vivax*," *J Exp Med* 169:1795-1802 (1989).
- Darbonne WC, Rice GC, Mohler MA, et al. "Red blood cells are a sink for interleukin-8, a leukocyte chemotaxin," *J Clin Invest* 88:1362-1369 (1991).
- 25 Chaudhuri A, Zbrzezna V, Polyakova J, Pogo AO, Hesselgesser J, Horuk R. "Expression of the Duffy antigen in K562 cells. Evidence that it is the human erythrocyte chemokine receptor," *J Biol Chem* 269:7835-7838 (1994).
- Rudbach JA, Cantrell JL, Ulrich JT. "Methods of immunization to enhance the immune response to specific antigens in vivo in preparation for fusions yielding monoclonal antibodies." In: Davis WC, ed., *Monoclonal Antibody Protocols*. Humana Press, Totowa, NJ, pp. 1-8 (1995).
- 30

Gorny MK. "Production of human monoclonal antibodies via fusion of Epstein-Barr virus-transformed lymphocytes with heteromyeloma." In: Cellis JE, ed., *Cell Biology: A Laboratory Handbook*. Academic Press, San Diego, CA, pp. 276-281 (1994).

5 Pinkert CA, MH Irwin, and RJ Moffatt, "Transgenic animal modeling." In: Myers RA, ed., *Molecular Biology and Biotechnology: A Comprehensive Desk Reference*. VCH Publishers, Inc., New York, pp. 901-907 (1995).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANTS: Reid, Marion E
- (ii) TITLE OF INVENTION: METHOD OF MAKING MONOCLONAL ANTIBODIES USING POLYMORPHIC TRANSGENIC ANIMALS
- (iii) NUMBER OF SEQUENCES: 3
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Hoffmann & Baron, LLP
 - (B) STREET: 350 Jericho Turnpike
 - (C) CITY: Jericho
 - (D) STATE: New York
 - (E) COUNTRY: USA
 - (F) ZIP: 11753
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
 - (B) COMPUTER: IBM compatible
 - (C) OPERATING SYSTEM: MS-DOS
 - (D) SOFTWARE: WordPerfect
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION INFORMATION:
 - (A) APPLICATION NUMBER: 08/749,527
 - (B) FILING DATE: 15-NOV-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: O'Dea, Sean W.
 - (B) REGISTRATION NUMBER: 37690
 - (C) REFERENCE/DOCKET NUMBER: 454-13 PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (516) 822-3550
 - (B) TELEFAX: (516) 822-3582

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3523 nucleotides
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTGCAGGGGT AGATGCCCTT TCTCTCTGCT GGCCAGCTCT GCCCCTCAGT	50
GAGAAACTTT ACATATTGCT AAGATGCCTG GCCAATGAAA CAGTTCCAGA	100
GACTTTATGT CCCCAGTAGA AATATGAATA GAAATCACCC TGTGCTCAAT	150
GGTCCCATTT TAAAATATGC TGTCCCATTTG TCCCCTAGAG CCTATCTTAA	200
CTTGTCAGAC CATGTATTCC ACTTCATATG CAAGAGGCAT GCACTGAGCC	250
CATAGGTGGC TAGGCAAACA CCCAATAGCT CCCTGAAATG GCTTCATTAT	300
GGAGGCTCGA CAGCCACCCC AACCCCTCCA CTCTCACACT GAAACACCCA	350
GACCTAGAGA TAGCTAGACA CACCCAGACA CCCGCCAAGC CCCTCACATA	400
CAGATATGTG CACAATGATA CACAGCAAAT GTACACAGAG TTCAGTACAC	450
ACAAAGAGCT CACGCCCACG TGCACACACC CCTCAGTTGG GACAGAGTTG	500
ACCACCACCA CCTTTCTCCC AAACACATGG CTTTGGAAGT GCCTTTCCTT	550
GGATCCAGTT CAAGGGGATG GAGGAGCAGT GAGAGTCAGC CGCCCTTCCA	600
CTCCAATTTT CCAGCACCTC CTTTATCTCT GCCTCACAAG TCACCCAGCC	650
CCCCTCTCTT CCTTCCTTGT GCTTGAAGAA TCTCTCCTTG CTGGAAAGCC	700
CCCTGTTTTT TCAATCTCCC TTTCCACTTC GGTAATATCT CTCCTTGCTG	750
GAAAGCCCCC TGTTTTCTCA ATCTCCCTTT CCACTTCGGT AAAATGCCCA	800
CTTTCTGGTC CCCACCTTTT TCCTGAGTGT AGTCCCAACC AGCCAAATCC	850
AACCTCAAAA CAGGAAGACC CAAGGCCAGT GACCCCAATA GGCCTGAGGC	900
TTGTTGCAGG CAGTGGGCGT GGGGTAAGGC TTCCTGATGC CCCCTGTCCC	950
TGCCCAGAAC CTGATGGCCC TCATTAGTCC TTGGCTCTTA TCTTGGAAGC	1000
ACAGGCGCTG ACAGCCGTAC CAGCCCTTCT GTCTGCGGGC CTGAACCAAA	1050
CGGTGCCATG GGGAAGTGTC TGCACAGGGT GAGTATGGGG CCAGGCCCCA	1100

GAGTCCCTTA	TCCCTATGCC	CCTCATTTCC	CCTGCTGTTT	CCCCCTCAGT	1150
CTTTATATCT	CTTCCTTTTC	CTCCTCATCT	TTTCTCCCTT	CCTGCTTTTT	1200
TCCTCTTCCT	TCAAAGTCTT	TTTCCTTTTC	TCCTTCCTAT	GCTAGCCTCC	1250
TAGCTCCCTC	TTGTGTCCCT	CCCTTTGCCT	TTGAGTCAGT	TCCATCCTGG	1300
TCTCTTGGTG	CCTTTCCTTC	TGACCTTGCA	CTGCTCCTCC	AGCCCCAGCT	1350
GCCCTGGCTT	CCCCAGGACT	GTTCTTGCTC	CGGCTCTTCA	GGCTCCCTGC	1400
TTTGTCTTTT	TCCACTGTCC	GCACTGCATC	TGACTCCTGC	AGAGACCTTG	1450
TTCTCCCACC	GCACCTTCCT	CTCTGTCTC	CCCTCCCACC	TGCCCCTCAG	1500
TTCCCAGGAG	ACTCTTCCGG	TGTAACCTCTG	ATGGCCTCCT	CTGGGTATGT	1550
CCTCCAGGCG	GAGCTCTCCC	CCTCAACTGA	GAACCTCAAGT	CAGCTGCAGT	1600
TCGAAGATGT	ATGGAATTCT	TCCTATGGTG	TGAATGATTC	CTTCCCAGAT	1650
GGAGACTATG	ATGCCAACCT	GGAAGCAGCT	GCCCCCTGCC	ACTCCTGTAA	1700
CCTGCTGGAT	GACTCTGCAC	TGCCCTTCTT	CATCCTCACC	AGTGTCTTGG	1750
GTATCCTAGC	TAGCAGCACT	GTCCTCTTCA	TGCTTTTCAG	ACCTCTCTTC	1800
CGCTGGCAGC	TCTGCCCTGG	CTGGCCTGTC	CTGGCACAGC	TGGCTGTGGG	1850
CAGTGCCCTC	TTCAGCATTG	TGGTGCCCGT	CTTGGCCCCA	GGGCTAGGTA	1900
GCACTCGCAG	CTCTGCCCTG	TGTAGCCTGG	GCTACTGTGT	CTGGTATGGC	1950
TCAGCCTTTG	CCCAGGCTTT	GCTGCTAGGG	TGCCATGCCT	CCCTGGGCCA	2000
CAGACTGGGT	GCAGGCCAGG	TCCCAGGCCT	CACCCTGGGG	CTCACTGTGG	2050
GAATTTGGGG	AGTCCGTGCC	CTACTGACAC	TGCCTGCTAC	CCTGGCCAGT	2100
GGTGCTTCTG	GTGGACTCTG	CACCCTGATA	TACAGCACGG	AGCTGAAGGC	2150
TTTGCAGGCC	ACACATACTG	TAGCCTGTCT	TGCCATCTTT	GTCTTGTTGC	2200
CATTGGGTTT	GTTTGGAGCC	AAGGGGCTGA	AGAAGGCATT	GGGTATGGGG	2250
CCAGGCCCCCT	GGATGAATAT	CCTGTGGGCC	TGGTTTATTT	TCTGGTGGCC	2300
TCATGGGGTG	GTTCTAGGAC	TGGATTTCCT	GGTGAGGTCC	AAGCTGTTGC	2350

TGTTGTCAAC ATGTCTGGCC CAGCAGGCTC TGGACCTGCT GCTGAACCTG	2400
GCAGAAGCCC TGGCAATTTT GCACTGTGTG GCTACGCCCC TGCTCCTCGC	2450
CCTATTCTGC CACCAGGCCA CCCGCACCCT CTTGCCCTCT CTGCCCCTCC	2500
CTGAAGGATG GTCTTCTCAT CTGGACACCC TTGGAAGCAA ATCCTAGTTC	2550
TCTTCCCACC TGTCAACCTG AATTAAAGTC TACACTGCCT TTGTGAAGCG	2600
GGTGGTTTCT TATTTTGTCT GGGGAGAAGA AGGAGAATGG AGAGAGAGAC	2650
ATTTTTATGT CAGACTTTCT TGCCAGTGTC TGCTTCTATA GCTGGCTTGG	2700
GAAGAAGGTG AATGATGAAT AAATACCCTC AGGGTACACA GATGTTCTCT	2750
TGAGGTGTGG GGTCAAGCCA TCTCAAGGGA GAAGAGAAGA GGAAC TAGAG	2800
CATGAGGGGA GTCATTAAAC CAAAAAAAC AGAAGGGATG GCTTAGCTGG	2850
AAAAAAGCT GTTCTGGGAA GCAAATGGAA TAGGAACTCA AACTGAGAGA	2900
TAAACAGTGA AGAGTGATGA CAAAGCCCAG AGCAATACCA CCTCCCCCTG	2950
TCCAACCTGC CCAGCCTCTG TCTTCTGTCT CCTCTCTGGC TTTGTTTAGT	3000
GATTAGGACA GTGGTGGGGA AGGTGAAAGA AGCATCCCAG GGGATGTTAC	3050
TCAGTTCAGG GAACATATCA AGGTAATTTA AAAAGCCACT TCCTGGGAGT	3100
CATCTCTCCC AGGTTCTCA GCATGACCTG AATGTGTGTG TGTGCGTGTG	3150
TGTGTGTGTG TGTACACATC TGTTTCTCGA TCTGTTAGAA TCTACCTTTA	3200
TGTTAGATGT ATGCATGTAA AAACATATGT CCACCCATGA GCTTGCATCT	3250
CTGCTAGCAC CTGAACTGCG ACACCTGTGC GTGTGCACTG ACTTTTCTCA	3300
GGACCCAAAC CCCCACTCAA TTCTGCACTC ATCCCTGTTC ACAGGATATA	3350
GAATCGGGAT TTATGACTCA CTCCTTACCC AAATGAGTTT TCTTTACCCT	3400
GGTTTTTAAG CCTAGTCTTT TCTGTGTAGG ATGTGTGGAG GGAAGAAAAG	3450
ATCAAGAAGT TGTGAGGGGT GGAGAACTT GAAGGGGGAG GCCCTGATTT	3500
GATTCATCTT CTGCTTGGA TTC	3523

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 nucleotides
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CTGCAGGGGT AGATGCCCTT TCCTC

24

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 nucleotides
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAATTCCAAG CAGAAGATGA ATC

23

WHAT IS CLAIMED IS:

1. A method for making an antibody, comprising:
constructing a first transgenic animal to express a first form of an exogenous
polymorphic protein encoded by a first allele of a gene encoding the protein;
constructing a second transgenic animal to express a second form of the polymorphic
5 protein encoded by a second allele of the gene encoding the protein;
immunizing said first transgenic animal with cells from said second transgenic animal
expressing said second form of the polymorphic protein to induce an immune response in said
first transgenic animal yielding an antibody specific for an epitope characteristic of said second
form of the polymorphic protein; and
10 isolating the antibody.
2. A method according to Claim 1, further comprising isolating from said first
transgenic animal a lymphoid cell capable of producing said antibody.
3. A method according to Claim 2, further comprising fusing said antibody-producing
lymphoid cell with an immortal cell to provide an antibody-producing hybridoma cell.
4. A method according to Claim 1, wherein said polymorphic protein is expressed on a
cell membrane.
5. A method according to Claim 4, wherein said polymorphic protein is a blood group
protein.
6. A method according to Claim 5, wherein said blood group protein is gp-Fy protein.
7. A method according to Claim 1, wherein said polymorphic protein is a human
polymorphic protein.
8. A method according to Claim 1, wherein said first transgenic animal and said
second transgenic animal are both transformed from animals of one inbred strain.

9. A method according to Claim 1, wherein said first and second transgenic animals are mice.

10. A hybridoma cell that cannot be routinely made by standard methods, produced by a method comprising:

constructing a first transgenic animal to express a first form of an exogenous polymorphic protein encoded by a first allele of a gene encoding the protein;

5 constructing a second transgenic animal to express a second form of the polymorphic protein encoded by a second allele of the gene encoding the protein;

immunizing said first transgenic animal with cells from said second transgenic animal expressing said second form of the polymorphic protein to induce an immune response in said first transgenic animal yielding an antibody specific for an epitope characteristic of said second
10 form of the polymorphic protein;

isolating from said first transgenic animal a lymphoid cell capable of producing said antibody; and

fusing said antibody-producing lymphoid cell with an immortal cell to provide an antibody-producing hybridoma cell.

11. A hybridoma cell according to Claim 10, wherein said polymorphic protein is a blood group protein, and said hybridoma cell is capable of producing an antibody specific for an epitope characteristic of said second form of said blood group protein.

12. A hybridoma cell according to Claim 11, wherein said blood group protein is gp-Fy protein, and said hybridoma cell is capable of producing an antibody specific for an epitope characteristic said second form of gp-Fy protein.

13. An antibody specific for an epitope characteristic of one form of a polymorphic protein, produced by a method comprising:

constructing a first transgenic animal to express a first form of an exogenous polymorphic protein encoded by a first allele of a gene encoding the protein;

- 5 constructing a second transgenic animal to express a second form of the polymorphic protein encoded by a second allele of the gene encoding the protein;
 immunizing said first transgenic animal with cells from said second transgenic animal expressing said second form of the polymorphic protein to induce an immune response in said first transgenic animal yielding an antibody specific for an epitope peculiar to said second form
10 of the polymorphic protein; and
 isolating said antibody.

14. An antibody according to Claim 13, wherein said method further comprises:
 isolating from said first transgenic animal a lymphoid cell capable of producing said antibody; and
15 fusing said antibody-producing lymphoid cell with an immortal cell to provide a hybridoma cell which produces said antibody.

15. A monoclonal antibody according to Claim 13, wherein said polymorphic protein is a blood group protein, and said monoclonal antibody is specific for an epitope characteristic of said second form of said blood group protein.

16. A monoclonal antibody according to Claim 13, wherein said blood group protein is gp-Fy protein and said monoclonal antibody is specific for an epitope characteristic of said second form of gp-Fy protein.

17. A method for making an antibody, comprising:
 constructing a transgenic animal to express a first form of an exogenous polymorphic protein encoded by a first allele of a gene encoding the protein;
 immunizing said transgenic animal with a peptide comprising an epitope characteristic
5 of a second form of the polymorphic protein to induce an immune response in said transgenic animal yielding an antibody specific for said epitope.

18. A method according to Claim 17, further comprising isolating from said transgenic animal a lymphoid cell capable of producing said antibody.

19. A method according to Claim 18, further comprising fusing said antibody-producing lymphoid cell with an immortal cell to provide an antibody-producing hybridoma cell.
20. A method according to Claim 17, wherein said polymorphic protein is expressed on a cell membrane.
21. A method according to Claim 20, wherein said polymorphic protein is a blood group protein.
22. A method according to Claim 21, wherein said blood group protein is gp-Fy protein.
23. A method according to Claim 17, wherein said polymorphic protein is a human polymorphic protein.
24. A method according to Claim 17, wherein said transgenic animal is a mouse.




FIGURE 1

2/6




FIGURE 2

Sense-primer for DNA amplification

CTGCAGGGGT AGATGCCCTT TCTCTCTGCT GGCCAGCTCT GCCCTCAGT GAGAACTTT	60
ACATATTGCT AAGATGCCTG GCCAATGAAA CAGTTCAGA GACTTTATGT CCCAGTAGA	120
AATATGAATA GAAATCACCC TGTGGGCAAT GGTCCTATT TAAATATGC TGTCCCATG	180
TCCCCTAGAG CCTACTTTAA CTTGTCAGAC CATGTATTCC ACTTCATATG CAAGAGGCAT	240
GCACTGAGCC CATAGGTGGC TAGGCAAACA CCAATAGCT CCCTGAAATG GCTTCATTAT	300
GGAGGCTCGA CAGCCACCCC AACCTCCCA CTCTCACACT GAAACACCCA GACCTAGAGA	360
TAGCTAGACA CACCCAGACA CCCGCCAAGC CCCTCACATA CAGATATGTG CACAATGATA	420
CACAGCAAAT GTACACAGAG TTCAGTACAC ACAAAGAGCT CACGCCCACG TGCACACACC	480
CCTCAGTTGG GACAGAGTTG ACCACCACCA CCTTTCTCCC AAACACATGG CTTTGGAAT	540
GCCTTTCCTT GGATCCAGTT CAAGGGGATG GAGGAGCAGT GAGAGTCAGC CGCCCTTCCA	600
CTCCAATTC CCAGCACCTC CTTATCTCT GCCTCACAAG TCACCCAGCC CCCCTCTCTT	660
CCTTCCTTGT GCTTGAAGAA TCTCTCCTTG CTGGAAAGCC CCCTGTTTTT TCAATCTCCC	720
TTTCCACTTC GGTAAATCT CTCCTTGCTG GAAAGCCCC TGTTTTCTCA ATCTCCCTTT	780
CCACTTCGGT AAAATGCCCA CTTTCTGGTC CCCACCTTTT TCCTGAGTGT AGTCCCAACC	840
AGCCAAATCC AACCTCAAAA CAGGAAGACC CAAGGCCAGT GACCCCATATA GGCCTGAGGC	900
TTGTTGCAGG CAGTGGGCGT GGGGTAAGGC TTCCTGATGC CCCCTGTCCC TGCCAGAAC	960
CTGATGGCCC TCATTAGTCC TTGGCTCTTA TCTTGGAAGC ACAGGCGCTG ACAGCCGTAC	1020
CAGCCCTTCT GTCTCGGGC CTGAACCAAA CGGTGCCATG GGGAACTGTC TGCACAGGGT	1080
GAGTATGGGG CCAGGCCCCA GAGTCCCTTA TCCCTATGCC CCTCATTTCC CTGCTGTTT	1140
GCCCCTCAGT CTTTATATCT CTTCTTTTC CTCTCATCT TTTCTCCCTT CTGCTTTTT	1200
TCCTTTCCT TCAAAGTCTT TTTCTTTTC TCCTTCCTAT GCTAGCCTCC TAGCTCCCTC	1260
TTGTGTCCCT CCCTTGCCT TTGAGTCAGT TCCATCCTGG TCTCTGGTG CTTTCTCTC	1320
TGACCTTGCA CTGCTCCTCC AGCCCCAGCT GCCCTGGCTT CCCAGGACT GTTCTGCTC	1380
CGGCTCTTCA GGCTCCCTGC TTTGTCTTT TCCACTGTCC GCACTGCATC TGAATCCTGC	1440
AGAGACCTTG TTCTCCACC CGACCTTCT CTCTGTCTC CCCTCCCACC TGCCCTCAG	1500
TTCCAGGAG ACTCTCCGG TGTAAGTCTG <u>ATGGCTCTCT</u> CTGGGTATGT CCTCCAGGCG	1560
GAGCTCTCCC CCTCAACTGA GAACTCAAGT CAGCTGGACT TCGAAGATGT ATGGAATTCT	1620
TCCTATGGTG TGAATGATTC CTTCCAGAT GGAGACTATG <u>ATGCCAACCT</u> GGAAGCAGCT	1680
GCCCCCTGCC ACTCCTGTAA CCTGCTGGAT GACTCTGCAC TGCCCTTCTT CATCCTCACC	1740


Initial codon of Duffy GP open reading frame
 G in FYA Primer for mutagenesis

FIGURE 3A

AGTGTCTGG GTATCCTAGC TAGCAGCACT GTCCTCTTCA TGCTTTTCAG ACCTCTCTTC 1800
 CGCTGGCAGC TCTGCCCTGG CTGGCCTGTC CTGGCACAGC TGGCTGTGGG CAGTGCCCTC 1860
 TTCAGATTG TGGTGCCCGT CTTGGCCCCA GGGCTAGGTA GCACTCGCAG CTCTGCCCTG 1920
 TGTAGCCTGG GCTACTGTGT CTGGTATGGC TCAGCCTTTG CCCAGGCTTT GCTGCTAGGG 1980
 TGCCATGCCT CCCTGGGCCA CAGACTGGGT GCAGGCCAGG TCCCAGGCCT CACCCTGGGG 2040
 CTCACTGTGG GAATTTGGGG AGTGGCTGCC CTA CTGACAC TGCCTGTCAC CCTGGCCAGT 2100
 GGTGCTTCTG GTGGACTCTG CACCCTGATA TACAGCACGG AGCTGAAGGC TTTGCAGGCC 2160
 ACACACACTG TAGCCTGTCT TGCCATCTTT GTCTTGTTC CATTGGGTTT GTTTGGAGCC 2220
 AAGGGGCTGA AGAAGGCATT GGGTATGGGG CCAGGCCCTT GGATGAATAT CCTGTGGGCC 2280
 TGGTTTATTT TCTGGTGGCC TCATGGGGTG GTTCTAGGAC TGGATTTCTT GGTGAGGTCC 2340
 AAGCTGTTGC TGTTGTCAAC ATGTCTGGCC CAGCAGGCTC TGGACCTGCT GCTGAACCTG 2400
 GCAGAAGCCC TGGCAATTTT GCACTGTGTG GCTACGCCCC TGCTCCTCGC CCTATTCTGC 2460
 CACCAGGCCA CCCGCACCCT CTTGCCCTCT CTGCCCCCTC CTGAAGGATG GTCTTCTCAT 2520
 CTGGACACCC TTGGAAGCAA ATCCTAGTTC TCTTCCCACC TGTC AACCTG AATTAAAGTC 2580
 TACTACTGCCT TTGTGAAGCG GGTGGTTTCT TATTTTGTCT GGGGAGAAGA AGGAGAATGG 2640
 AGAGAGAGAC ATTTTATGT CAGACTTTCT TGCCAGTGTC TGCTTCTATA GCTGGCTTGG 2700
 GAAGAAGGTG AATGATGAAT AAATACCCTC AGGGTACACA GATGTTCTCT TGAGGTGTGG 2760
 GGTGAGGCCA TCTCAAGGGA GAAGAGAAGA GGAAC TAGAG CATGAGGGGA GTCATTAAAC 2820
 CAAAAAAAC AGAAGGGATG GCTTAGCTGG AAAAAAGCT GTTCTGGGAA GCAATGGAA 2880
 TAGGAACTCA AACTGAGAGA TAAACAGTGA AGAGTGATGA CAAAGCCCAG AGCAATACCA 2940
 CCTCCCCCTG TCCAACCTGC CCAGCCTCTG TCTTCTGTCT CCTCTCTGGC TTTGTTTAGT 3000
 GATTAGGACA GTGGTGGGGA AGGTGAAAGA AGCATCCCAG GGGATGTTAC TCAGTTCAGG 3060
 GAACATATCA AGGTAATTTA AAAAGCCACT TCCTGGGAGT CATCTCTCCC AGGTTCTCTCA 3120
 GCATGACCTG AATGTGTGTG TGTGCGTGTG TGTGTGTGTG TGTACACATC TGTTTCTCGA 3180
 TCTGTTAGAA TCTACCTTTA TGTTAGATGT ATGCATGTAA AAACATATGT CCACCCATGA 3240
 GCTTGCACT CTGTCAGCAC CTGAACTGCG ACACCTGTGC GTGTGCACTG ACTTTTCTCA 3300
 GGACCCAAAC CCCCACTCAA TTCTGCACTC ATCCCTGTTC ACAGGATATA GAATCGGGAT 3360
 TTATGACTCA CTCCTTACCC AAATGAGTTT TCTTTACCCT GGTTTTAAAG CCTAGTCTTT 3420
 TCTGTGTAGG ATGTGTGGAG GGAAGAAAAG ATCAAGAAGT TGTGAGGGGT GGAGAACTT 3480
 GAAGGGGGAG GCCCTGATTT GATTCATCTT CTGCTTGAA TTC 3523
 Anti-sense primer for DNA amplification

FIGURE 3B

Fig. 8



6/6




FIGURE 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/20783

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 5/28, 5/24, 15/00, 15/09, 15/63, 5/10

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 430/320.1, 6, 69.1, 375; 800/2; 935/89, 62, 70, 93; 536/23.5; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN, BIOSIS, MEDLINE, EMBASE

search terms: transgenic, immunize, antibodies, hybridoma

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	HULTGREN et al. Antibodies to the hepatitis B e antigen (HBe-Ag) can be Induced in HBe-Ag-transgenic mice by adoptive transfer of a specific T-helper 2 cell clone. Clinical and Diagnostic Laboratory Immunology. September 1997, Vol. 4, No. 5, pages 630-632, see entire document.	1-24
Y	JAKOBOVITS et al. Production of Fully Human Antibodies by Transgenic Mice. Current Opinion in Biotechnology. October 1995, Vol. 6, No. 5, pages 561-566, see entire document.	1-24
Y	US 5,101,017 (RUBINSTEIN et al.) 31 March 1992, entire document, especially claims.	1-24

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

04 FEBRUARY 1998

Date of mailing of the international search report

23 FEB 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KAREN M. HAUDA

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/20783

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHAUDHURI et al. Purification and Characterization of an Erythrocyte Membrane Protein Complex Carrying Duffy Blood Group Antigenicity. Journal of Biological Chemistry. 15 August 1989, Vol. 264, No. 23, pages 13770-13774, see entire document.	1-24

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/20783

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

430/320.1, 6, 69.1, 375; 800/2; 935/89, 62, 70, 93; 536/23.5; 514/2




FIGURE 1

2/6




FIGURE 2

Sense-primer for DNA amplification

CTGCAGGGG7 AGATGCCCTT TCCTCTCTGCT GGCCAGCTCT GCCCTCAG7 GAGAACTTY	60
ACATATTGCT AAGATGCCTG GCCAATGAAA CAGTCCAGA GACTTTATGT CCCAGTAGA	120
AATATGAATA GAAATCACCC TGTGGGCAAT GGTCCCATTT TAAATATGC TGTCCCATTG	180
TCCCCTAGAG CTTACTTTAA CTGTCTAGAC CATGTATTCC ACTTCATATG CAAGAGGCAT	240
GCACTGAGCC CATAGGTGGC TAGGCAACA CCAATAGCT CCCTGAAATG GCTTCATTAT	300
GGAGGCTCGA CAGCCACCCC AACCTCCCA CTCTCAGCT GAAACACCCA GACCTAGAGA	360
TAGCTAGACA CACCAGACA CCGCCAAGC CCTCAGATA CAGATATGTG CACAATGATA	420
CACAGCAAT GTACACAGAG TTCAGTACAC ACAAAGAGCT CAGGCCCAGG TGCACACACC	480
CCTCAGTTGG GACAGAGTGG ACCACCACCA CCTTCTCCG AACACATGG CTTTGGAAC	540
GCCTTTCCTT GGATCCAGTT CAGGGGGATG GAGGAGCAGT GAGAGTCAGC CGCCCTTCCA	600
CTCCAAATTC CCAGCACCTC CTTTATCTCT GCCTCAGAG TCACCCAGCC CCCCCTCTTT	660
CCCTCTCTGT GCTTGAAGAA TCTCTCCTTG CTGGAAAGCC CCCTGTTTTG TCAATCTCCG	720
TTTCCACTTC GTTAAATCT CTCTTGCTG GAAAGCCCC TGTTTTCTCA ATCTCCCTTT	780
CCACTTCGGT AAAATGCCCA CTTTCTGGTC CCACCTTTT TCCTGAGTGT AGTCCCAACC	840
AGCCAAATCC AACCTCAAAA CAGGAAGACC CAAGGCCAGT GACCCCAATG GGCCTGAGGC	900
TTGTTCAGG CAGTGGCGT GGGGTAAGGC TTCTGATGC CCCCCTGCCC TGCCCAAGAC	960
CTGATGGCCC TCAFTAGTCC TTGGCTCTTA TCTTGAAGC ACAGGCBCTG ACAGCGGTAC	1020
CAGCCCTTCT GTCTGCGGC CTGAACCAA CGGTGCCATG GGGAACTGTC TGCACAGGGT	1080
GAGTATGGGG CCAGGCCCCA GAGTCCCTTA TCCCTATGCC CCTCATTTCC CTTGCTGTTT	1140
GCCCCTCAGT CTTTATATCT CTTCTTTTC CTCTCATCT TTTCTCCCTT CTGCTTTTTT	1200
TCTCTTCTT TCAAACTCTT TTCTCTTTC TCCTTCTAT GCTAGCCTCC TAGCTCCCTC	1260
TTGTGTCCCT CCCTTGGCT TTGAGTCAGT TCCATCCTGG TCTCTTGGTG CTTTCTCTTC	1320
TGACCTTGCA CTGCTCCTCC AGCCCCAGCT GCCCTGCTT CCCAGGACT GTTCTGCTC	1380
CGGCTCTTCA GGCTCCCTGC TTTGTCTTT TCACTGTCC GCACTGCATC TGACTCCTGC	1440
AGAGACCTTG TTCTCCACC CGACCTCTCT CTCTGTCTC CCCTCCACC TGCCCTCAG	1500
TTCCAGGAG ACTCTTCGG TGTAACTCTG <u>ATGGCTCTCT</u> CTGGTATGT CTECAGGC	1560
GAGCTCTCCC CCTCAACTGA GAACTCAAGT CAGCTGGACT TCGAAGATGT ATGGAATTCT	1620
TCCTATGGTG TGAATGATTC CTTECCAGAT GGAGACTATG <u>ATGCCAACCT</u> GGAAGAGCT	1680
GCCCCCTGCC ACTCTGTAA CTTGCTGGAT GACTCTGCAC TGCCCTCTT CATCTCACC	1740

FIGURE 3A

4/6

AGTGTCTGG GTATCCTAGC TAGCAGCACT GTCCTCTTCA TGCTTTTCAG ACCCTCTCTC 1800
 CGCTGGCAGC TCTGCCCTGG CTGGCCTGTC CTGGCACAGC TGGCTGTGGG CAGTGCCCTC 1860
 TTCAGCATTG TGGTGCCCGT CTTGGCCCA GGGCTAGGTA GCACTCGCAG CTCTGCCCTG 1920
 TGTAGCCTGG GCTACTGTGT CTGGTATGGC TCAGCCTTTG CCCAGGCTTT GCTGCTAGGG 1980
 TGCCATGCTT CCTGGGCCA CAGACTGGGT GCAGGCCAGG TCCAGGGCT CACCCTGGGG 2040
 CTCACTGTGG GAATTTGGGG AGTGECTGCC CTA CTGACAC TGCCTGTAC CCTGGCCAGT 2100
 GGTGCTTCTG GTGGACTCTG CACCCTGATA TACAGCACGG AGCTGAAGGC TTTGCAGGCC 2160
 ACACACACTG TAGCCTGTCT TGCCATCTTT GTCTTGTTC CATTGGGTTT GTTGGAGCC 2220
 AAGGGGCTGA AGAAGGCATT GGGTATGGGG CCAGGCCCTT GGATGAATAT CCTGTGGGCC 2280
 TGGTTATTT TCTGGTGCC TCATGGGGTG GTTCTAGGAC TGGATTTCCT GGTGAGGTCC 2340
 AAGCTGTTGC TGTGTCAAC ATGTCTGGCC CAGCAGGCTC TGGACCTGCT GCTGAACCTG 2400
 GCAGAAGCCC TGGCAATTT GCACTGTGTG GCTACGCCCC TGCTCCTCGC CCTATTCTGC 2460
 CACCAGGCCA CCGGCACCCT CTTGCCCTCT CTGCCCTCC CTGAAGGATG GTCTTCTCAT 2520
 CTGGACACCC TTGGAAGCAA ATCCTAGTTC TCTTCCACC TGTCAACCTG AATTAAAGTC 2580
 TACACTGCCT TTGTGAAGCG GGTGGTTTCT TATTTTGTCT GGGGAGAAGA AGGAGAATGG 2640
 AGAGAGAGAC ATTTTATGT CAGACTTTCT TGCCAGTGTC TGCTTCTATA GCTGGCTTGG 2700
 GAAGAAGGTG AATGATGAAT AATACCCCTC AGGGTACACA GATGTTCTCT TGAGGTGTGG 2760
 GGTGAGCCA TCTCAAGGA GAAGAAGA GGAAGTAGAG CATGAGGGGA GTCATTAAAC 2820
 CAAAAAAGC AGAAGGGATG GCTTAGCTGG AAAAAAGCT GTTCTGGGA GCAATGSA 2880
 TAGGAAGTCA AACTGAGAGA TAAACAGTGA AGAGTGATGA CAAAGCCCAG ASCAATACCA 2940
 CCTCCCCCTG TCCAACCTGC CCAGCCTCGT TCTTCTGTCT CCTCTCTGGC TTTGTTAGT 3000
 GATTAGSACA GTGGTGGGA AGGTGAAAGA AGCATCCCAG GGGATGTTAC TCAGTTCAGG 3060
 GAACATATCA AGGTAATTTA AAAAGCCACT TCCTGGGAGT CATCTCTCCC AGGTTCCTCA 3120
 GCATGACCTG AATGTGTGTG TGTGCTGTG TGTGTGTGTG TGTACACATC TGTCTCTCA 3180
 TCTGTIAGAA TCTACCTTTA TGTAGATGT ATGCATGTAA AACATATGT CCACCCATGA 3240
 GCTTGCACT CTGTACACAC CTGAAGTGGC ACACCTGTGC GTGTGCACTG ACTTTTCTCA 3300
 GGACCCAAAC CCCCCTCAA TTCTGCACTC ATCCTGTTC ACAGGATATA GAATCGGGAT 3360
 TTATGACTCA CTGCTTACCC AATGAGTTT TCTTACCCT GGTTTTAAAG CCTAGTCTTT 3420
 TCTGTGTAGG ATGTGTGGAG GGAAGAAAAG ATCAAGAAGT TGTGAGGGGT GGAGAACTT 3480
 GAAGGGGGAG GCCCTGATT GATTCATCTT CTGCTTGAAT TTC 3523
 Anti-sense primer for DNA amplification

FIGURE 3B

200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711

11 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1



6/6




FIGURE 5